The rise of copyright’s blockbuster initially fueled a boom for major pharmaceutical companies, but recent developments present a murky outlook for investors. Lower-cost versions are reducing revenue, and ongoing https://arunpkqv226056.blogdigy.com/the-blue-pill-and-the-pharmaceutical-industry-a-precarious-bet-66122769